We hypothesized that ADGRG6 is overexpressed in PAAD and predicts unfavorable clinical outcomes by promoting tumor cell proliferation and migration through NF-κB/STAT6-mediated signaling and modulation of the TME. This evidence concerns the gene ADGRG6 and neoplasm.